Evidence map›Paper›PMID 35336048›Full record

ArticlePharmaceutics2022

PLA

Milica Markovic, Shimon Ben-Shabat, Jagadeesh Nagendra Manda, Karina Abramov-Harpaz, Clil Regev, Yifat Miller, Aaron Aponick, Ellen M Zimmermann, Arik Dahan

Abstract read
In one paragraph

Article in Pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Milica MarkovicDepartment of Clinical Pharmacology, School of Pharmacy, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva 8410501, Israel.ORCID 0000-0002-3998-1833
Shimon Ben-ShabatDepartment of Clinical Pharmacology, School of Pharmacy, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva 8410501, Israel.ORCID 0000-0001-7551-5488
Jagadeesh Nagendra MandaDepartment of Chemistry, University of Florida, Gainesville, FL 32603, USA.
Karina Abramov-HarpazDepartment of Chemistry, Ben-Gurion University of the Negev, Beer-Sheva 8410501, Israel.ORCID 0000-0003-0272-0047
Clil RegevDepartment of Chemistry, Ben-Gurion University of the Negev, Beer-Sheva 8410501, Israel.
Yifat MillerDepartment of Chemistry, Ben-Gurion University of the Negev, Beer-Sheva 8410501, Israel.
Aaron AponickDepartment of Chemistry, University of Florida, Gainesville, FL 32603, USA.ORCID 0000-0002-4576-638X
Ellen M ZimmermannDepartment of Medicine, Division of Gastroenterology, University of Florida, Gainesville, FL 32610, USA.
Arik DahanDepartment of Clinical Pharmacology, School of Pharmacy, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva 8410501, Israel.ORCID 0000-0002-3498-3514

Funding

United States-Israel Binational Science Foundation 2015365
6 · The paper itself

Abstract

Oral medication with activity specifically at the inflamed sites throughout the gastrointestinal tract and limited systemic exposure would be a major advance in our therapeutic approach to inflammatory bowel disease (IBD). For this purpose, we have designed a prodrug by linking active drug moiety to phospholipid (PL), the substrate of phospholipase A

Indexed as

colonic brush border membrane vesiclescyclosporinedrug targetinginflammatory bowel diseaseoral drug deliveryphospholipase A2prodrug

Identifiers

PMID35336048
PMCPMC8950246

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.